Ado-trastuzumab emtansine is a type of targeted therapy drug called an antibody–drug conjugate. It is a monoclonal antibody chemically linked to a chemotherapy drug.

Nov 15, 2024 · ado-trastuzumab emtansine is used both for early breast cancer and for breast cancer that has spread to other parts of the body (metastatic). Ado-trastuzumab emtansine is usually given after other treatments have failed.

Trastuzumab emtansine is an antibody-drug conjugate (ADC), a combination between a monoclonal antibody and a small-molecule drug. Each molecule of trastuzumab emtansine consists of a single trastuzumab molecule with several molecules of DM1, a cytotoxic maytansinoid, attached. [21]

Mar 1, 2025 · Ado-trastuzumab emtansine injection is used to treat HER2-positive metastatic breast cancer (cancer that has spread) in patients who have previously received other medicines (eg, trastuzumab, taxane medicine) that did not work well or whose cancer has returned during or within 6 months of completing treatment.

Learn about KADCYLA® (ado-trastuzumab emtansine), a treatment for certain patients with early or metastatic HER2+ breast cancer. See Full Safety and Boxed Warnings for more information.

On May 3, 2019, the Food and Drug Administration approved ado-trastuzumab emtansine (KADCYLA, Genentech, Inc.) for the adjuvant treatment of patients with HER2-positive early breast cancer...

Ado-trastuzumab emtansine injection is used to treat a certain type of breast cancer that has spread to other parts of the body and has not improved or has worsened after treatment with other medications.

Find patient medical information for ado-trastuzumab emtansine intravenous on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

Dec 12, 2022 · What is this drug used for? It is used to treat breast cancer. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had.

Ado-trastuzumab emtansine is an anti-HER2 antibody-drug conjugate; the anti-HER2 antibody trastuzumab, a humanized IgG 1, is conjugated with the microtubule inhibitor DM1 (derivative of maytansine) via the linker MCC (4-[N-maleimidomethyl] cyclohexane-1-carboxylate).